Comparative Pharmacology
Head-to-head clinical analysis: LAMICTAL XR versus TEGRETOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMICTAL XR versus TEGRETOL.
LAMICTAL XR vs TEGRETOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate.
Voltage-gated sodium channel blocker; stabilizes neuronal membranes and inhibits repetitive firing. Also inhibits glutamate release and enhances GABA activity.
Lamotrigine extended-release tablets: Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 200 mg once daily; maintenance 200–400 mg once daily as adjunctive therapy for epilepsy. For bipolar disorder, dose titration as per prescribing information; typical maintenance 200 mg once daily.
Initial: 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Maintenance: 800-1200 mg/day in 2-4 divided doses. Maximum dose: 1600 mg/day. Extended-release: 200-400 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 25-33 hours in healthy adults, increasing to 50-60 hours in patients taking valproate, and decreasing to 15-27 hours in patients taking enzyme-inducing drugs like carbamazepine, phenytoin, or phenobarbital.
Single dose: 25–65 hours (mean ~35 h); chronic therapy: 12–17 hours due to autoinduction; clinical context: requires 3–4 weeks to reach steady-state after dose adjustment.
Primarily renal; ~70% of lamotrigine is excreted in urine as glucuronide conjugates, 10% as parent drug, and 20% via feces.
Primarily hepatic metabolism; ~72% excreted in urine (as metabolites, <2% unchanged), ~28% excreted in feces via bile.
Category C
Category C
Anticonvulsant
Anticonvulsant